- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
As a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention," a biomarker is also known as a biological marker.
Beginning with the earliest natural history of the disease, biomarkers describe the course of disease. With the help of biomarkers, one may forecast outcomes, choose therapies, and assess therapy outcomes by determining the susceptibility and severity of a disease.
Biomarkers provide special insight into the connections between environmental risk variables from a forensics and epidemiologic perspective.The search for biomarkers for cancer can involve genes, proteins, or even tumor markers. Somatic or germline biomarker testing are both options. It is a laboratory test to identify biomarkers in blood, tissues, and other bodily fluids.
When used in conjunction with a particular treatment, a biomarker test is referred to as a companion diagnostic test. Genetic testing, which assesses if a person has inherited mutations that increase their risk of developing cancer, is different from biomarker testing.
These biomarkers are used to assess the likelihood that a patient will get an illness or medical condition even if they are not currently afflicted with one. Safety biomarkers foretell harmful side effects brought on by medication, medical, or even environmental agent exposure.
According to their clinical uses, biomarkers can be categorized as molecular, cellular, or imaging biomarkers.
The Global Cellular Biomarker market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The PlexAPR test is a blood test that was created in a lab as a cellular biomarker for the RAPID evaluation of the risk of rejection of transplanted abdominal organs byPlexision.
Anti-donor antibodies, which are made by recipient B-cells, or recipient T-cells, which directly harm the transplanted organ, may be to blame for this rejection.
By doing biopsies, rejection is diagnosed. When clinical signs and blood tests indicate there may be organ malfunction following transplantation, biopsies are carried out.
The invasive nature of biopsies, the length of time required to organise them, and their inability to distinguish between various viral infections that may coexist with rejection are all factors.
While confirmatory biopsies are being planned, quick non-invasive evaluation of the risk of rejection within a few hours might let the physician respond more promptly and better manage transplanted organs exhibiting organ failure.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.